Skip to content
10-K/A

Annual Report

Aspire Biopharma Holdings, Inc. ASBP ASBPW

0001493152-26-015737

← back to feed
Filed
Apr 8, 2026 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 5.02M sh
Shares Diluted FY 2025 · Dec 31, 2025 1.49M sh
Shares Diluted FY 2025 · Dec 31, 2024 689.91K sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$4.92M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$265.19K
Stockholders Equity FY 2025 · Dec 31, 2025 −$6.38M
Stockholders Equity restated FY 2025 · Dec 31, 2024 −$1.54M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$487.86K
Current Liabilities FY 2025 · Dec 31, 2025 $7.59M
Current Liabilities restated FY 2025 · Dec 31, 2024 $1.69M
Total Liabilities FY 2025 · Dec 31, 2025 $7.69M
Total Liabilities restated FY 2025 · Dec 31, 2024 $1.69M
Current Assets FY 2025 · Dec 31, 2025 $1.31M
Current Assets restated FY 2025 · Dec 31, 2024 $147.99K
Total Assets FY 2025 · Dec 31, 2025 $1.31M
Total Assets restated FY 2025 · Dec 31, 2024 $147.99K
Eps Diluted FY 2025 · Dec 31, 2025 −$16.38
Eps Diluted FY 2025 · Dec 31, 2024 −$1.90
Sga Expense FY 2025 · Dec 31, 2025 $17.64M
Sga Expense restated FY 2025 · Dec 31, 2024 $940.42K
Rd Expense FY 2025 · Dec 31, 2025 $923.91K
Rd Expense FY 2025 · Dec 31, 2024 $144.36K
Net Income FY 2025 · Dec 31, 2025 −$24.48M
Net Income restated FY 2025 · Dec 31, 2024 −$1.31M
Operating Income FY 2025 · Dec 31, 2025 −$19.35M
Operating Income FY 2025 · Dec 31, 2024 −$1.21M
Gross Profit FY 2025 · Dec 31, 2025 −$116
Cost Of Revenue FY 2025 · Dec 31, 2025 $6.32K
Revenue FY 2025 · Dec 31, 2025 $6.2K